Besins Healthcare — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Besins Healthcare is a fifth-generation, privately-held European biopharmaceutical company and a global leader in body-identical hormone therapies. With a commercial-stage portfolio centered on reproductive health and menopause, the company leverages deep expertise in hormone science and a vertically integrated manufacturing approach. It maintains a global commercial footprint, supported by over 1,600 employees, and emphasizes patient education and healthcare professional partnerships to drive growth in its core therapeutic areas.

Reproductive HealthMenopauseGynecology

Technology Platform

Expertise in the development, formulation, and manufacturing of body-identical (bio-identical) steroid hormone therapies.

Opportunities

Significant demographic tailwinds from the growing and increasingly vocal population of women seeking treatment for menopause symptoms.

Further opportunity exists in expanding global access to its established hormone therapies in underserved markets and through continued lifecycle management and education initiatives.

Risk Factors

High concentration in hormone therapies exposes the company to class-wide regulatory or safety issues.

As a private company, it may have less financial flexibility for large-scale R&D or acquisitions compared to public competitors, and its mature products face ongoing generic competition and pricing pressure.

Competitive Landscape

Besins competes in the hormone therapy market with large pharmaceutical companies (e.g., Pfizer, Bayer, Novo Nordisk) and generic manufacturers. Its differentiation is its long-standing specialization in body-identical hormones, family-owned stewardship, and deep focus on patient and HCP education in reproductive health and menopause.

More companies in Small Molecule Drugs →More companies in Europe - Other →